Ascendis Pharma closed 2025 with a sharp inflection in rare endocrine commercialization, reporting €684 million in product revenue for the year and €240 million in the fourth quarter, led by Yorvipath (TransCon PTH) at €477 million and Skytrofa (TransCon hGH) at €206 million. The company generated a fourth-quarter operating profit and €73 million in operating cash flow, ended the year with €616 million in cash, and is initiating a $120 million share repurchase in 2026. On the regulatory front, TransCon CNP for pediatric achondroplasia is under FDA priority review with a February 28, 2026 PDUFA date, and an EMA decision is anticipated in the fourth quarter of 2026.
The momentum reframes Ascendis from a platform story to a scaled rare disease operator. The strategic question now is whether the company can sustain access, adherence, and evidence generation at a pace that matches its commercial curve, while expanding into adjacent pediatric skeletal disorders where payer scrutiny and comparator pressure will be higher.
Yorvipath’s trajectory is redefining the hypoparathyroidism market, a category with limited direct PTH replacement options. More than 5,300 unique U.S. patient enrollments and prescribing activity from nearly 2,400 clinicians signal rapid penetration across endocrinology and nephrology. For payers, three-year pooled data showing sustained improvements in kidney function strengthen the clinical value story beyond symptom control, a critical lever for durable coverage. The confirmed once-weekly TransCon PTH profile aimed at patients stabilized on daily dosing could extend the product’s lifecycle and improve persistence, while real-world evidence will be essential to validate outcomes, dosing transitions, and healthcare resource utilization. Outside the U.S., access is broadening via commercial and named-patient pathways in over 30 countries, with full launches expected in 10 more by year-end 2026—an opportunity that also tests pricing discipline and HTA alignment across heterogeneous markets.
Achondroplasia is the next major catalyst. TransCon CNP would enter a market already shaped by daily CNP analog therapy, so weekly dosing, proportionality benefits, and longer-term functional outcomes will need to carry the differentiation case. Early combination data with TransCon CNP plus TransCon hGH showing growth velocities above the 97th percentile, alongside improvements in body proportionality, suggest a potential shift from height replacement toward disease modification. Regulators and payers will focus on functional endpoints, quality of life, orthopedic sequelae, and long-term safety, particularly in infants and adolescents where label expansions are being pursued.
Skytrofa’s 2025 adult GHD label expansion and the launch of a phase 3 basket program across idiopathic short stature, SHOX deficiency, Turner syndrome, and small for gestational age point to a scalable endocrine franchise architecture. Internationally, China approval of lonapegsomatropin via the VISEN partnership and Yorvipath’s commercial availability in Japan through Teijin validate Ascendis’ regionalization model. Meanwhile, the Novo Nordisk collaboration to advance TransCon-based therapies in obesity, including a TransCon semaglutide entry into the clinic, and a 2026 clinical start for TransCon aVEGF in retinal disease, signal platform portability into high-volume arenas where dosing convenience and durability could disrupt incumbents.
Financially, the company is guiding to significant operating cash generation in 2026 while carrying elevated SG&A from global launches. The balance to watch is commercial speed versus margin maturation, as manufacturing scale, patient services, and HEOR investments intensify. Optionality in oncology, with median overall survival data in platinum-resistant ovarian cancer expected this year, offers upside but remains outside the near-term revenue engine.
If TransCon CNP secures approval and the combination strategy progresses, Ascendis could convert an endocrine niche into a defensible multi-asset franchise. The open question for 2026: can the company lock in payer durability and clinical differentiation fast enough—before competitive responses and HTA recalibrations compress the window for premium growth across rare endocrine and pediatric skeletal disorders?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
